| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
The specific molecular targets of D,L-3-Indolylglycine are not fully characterized. As an unnatural amino acid similar to tryptophan, it may interact with tryptophan-binding proteins, enzymes, and receptors. The compound can be used for functional protein design, where it is incorporated into proteins to study structure-function relationships. Its structural similarity to tryptophan suggests potential interactions with tryptophan transporters, serotonin receptors, and other tryptophan-related biological targets. However, detailed target identification studies are limited.
|
|---|---|
| ln Vitro |
In vitro studies on D,L-3-Indolylglycine are limited, as the compound is primarily used as a research tool in biochemical and pharmaceutical research. The compound's structural similarity to tryptophan makes it useful for studying tryptophan metabolism, protein structure, and enzyme function. It can be used in functional protein design to probe protein structure and function. However, specific in vitro activity data such as IC50 values or detailed mechanistic studies are not widely available in the published literature.
|
| ln Vivo |
In vivo studies on D,L-3-Indolylglycine are limited. As an unnatural amino acid, the compound is not intended for therapeutic use and is primarily used as a research tool. Its structural similarity to tryptophan suggests potential effects on tryptophan metabolism and related pathways in vivo, but specific studies have not been published. The compound may be used in animal studies to investigate the effects of amino acid analogs on protein synthesis and function, but detailed in vivo data are not available.
|
| Enzyme Assay |
The in vitro binding assays for D,L-3-Indolylglycine are not well-documented. As an unnatural amino acid, the compound's interactions with potential molecular targets could be studied using standard biochemical techniques. These might include binding assays for tryptophan-binding proteins, enzyme activity assays for enzymes that recognize tryptophan, and cell-based assays for tryptophan transport and metabolism. However, specific protocols for studying D,L-3-Indolylglycine have not been published. Researchers would need to develop protocols based on the compound's structural similarity to tryptophan.
|
| Cell Assay |
Cellular assays for D,L-3-Indolylglycine are conducted using cell lines to study its effects on protein synthesis, amino acid transport, and cellular metabolism. Cells are treated with varying concentrations of the compound, and its incorporation into proteins, effects on cell viability, and effects on tryptophan metabolism are assessed. The compound can also be used in functional protein design studies, where it is incorporated into proteins expressed in cells to study structure-function relationships. However, detailed cell-based protocols for this compound are not widely published.
|
| Animal Protocol |
In vivo animal studies for D,L-3-Indolylglycine are not well-documented. As a research amino acid analog, the compound may be used in animal studies to investigate the effects of unnatural amino acids on protein synthesis, metabolism, and physiological function. However, specific in vivo protocols for D,L-3-Indolylglycine have not been published. Researchers interested in studying this compound would need to develop protocols based on its structural similarity to tryptophan and its potential applications in protein design and metabolism research.
|
| ADME/Pharmacokinetics |
D,L-3-Indolylglycine has a molecular weight of 190.20 and a molecular formula of C10H10N2O2. The compound appears as a solid powder. For research use, D,L-3-Indolylglycine is typically stored as powder at room temperature or at 4degC for long-term storage. The compound is soluble in water and other appropriate solvents for biochemical assays. Detailed pharmacokinetic parameters such as oral bioavailability, half-life, and tissue distribution have not been determined, as the compound is used primarily as a research tool rather than as a therapeutic agent.
|
| Toxicity/Toxicokinetics |
Toxicological data for D,L-3-Indolylglycine are limited. As an unnatural amino acid used primarily for research purposes, the compound has not been systematically evaluated for toxicity in preclinical studies. Standard safety precautions should be followed when handling the compound, including the use of appropriate personal protective equipment. The compound is for research use only and not for human therapeutic use. Researchers should consult the Safety Data Sheet (SDS) for specific safety information.
|
| Additional Infomation |
D,L-3-Indolylglycine (CAS#: 6747-15-5) is an unnatural amino acid similar to tryptophan, with the indole moiety directly attached to the alpha-position. It has a molecular formula of C10H10N2O2 and a molecular weight of 190.20. The compound is used in biochemical and pharmaceutical research, particularly for functional protein design and studying tryptophan-related biological processes. D,L-3-Indolylglycine is not approved for clinical use and is available only for research purposes.
|
| Molecular Formula |
C10H10N2O2
|
|---|---|
| Molecular Weight |
190.1986
|
| Exact Mass |
190.074
|
| CAS # |
6747-15-5
|
| PubChem CID |
438674
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
438.6±35.0 °C at 760 mmHg
|
| Melting Point |
215-218ºC
|
| Flash Point |
219.0±25.9 °C
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
| Index of Refraction |
1.726
|
| LogP |
0.87
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
14
|
| Complexity |
232
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
AIZGBPJAKQNCSD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H10N2O2/c11-9(10(13)14)7-5-12-8-4-2-1-3-6(7)8/h1-5,9,12H,11H2,(H,13,14)
|
| Chemical Name |
2-amino-2-(1H-indol-3-yl)acetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~4.63 mg/mL (~24.34 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.2576 mL | 26.2881 mL | 52.5762 mL | |
| 5 mM | 1.0515 mL | 5.2576 mL | 10.5152 mL | |
| 10 mM | 0.5258 mL | 2.6288 mL | 5.2576 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
